Akeso's Cancer Drug Triumphs Over AstraZeneca's Imfinzi in Phase 3 Trial
By Editor • August 27, 2026 • 1 min read
In a significant advancement for the Chinese biopharmaceutical sector, Akeso announced on Wednesday that its immunotherapy drug, ivonescimab, has surpassed AstraZeneca's Imfinzi in a pivotal phase 3 trial focused on biliary tract cancer.
This promising outcome marks yet another milestone for ivonescimab, which has already garnered attention with a multibillion-dollar licensing agreement with US-based Summit Therapeutics.
The trial, conducted in China, evaluated the efficacy of ivonescimab in combination with chemotherapy, showcasing the growing capabilities of China’s biopharma industry on the international front.
Source: www.scmp.com
#Akeso #AstraZeneca #biliary tract cancer #Imfinzi #ivonescimab
